16:03 EDT Vanda Pharmaceuticals (VNDA) sees FY25 revenue $210M-$250M, consensus $224.84M
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VNDA:
- Vanda Pharmaceuticals Advances with Promising Social Anxiety Disorder Treatment Study
- Vanda Pharmaceuticals Advances Dry Eye Treatment with VSJ-110 Study
- Vanda Pharmaceuticals Completes Key Bioequivalence Study for Schizophrenia and Bipolar Disorder Treatment
- VNDA Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Vanda’s FDA Agreement Boosts Buy Rating with Expedited Drug Reviews